Open an account

Evolent Health

EVH · NYSE

$4.87+$0.39 (+8.71%)TodayMarket closed ·
Prev close $4.48

About EVH

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. The company is headquartered in Arlington, Virginia and currently employs 4,200 full-time employees. The company went IPO on 2015-06-05. The firm offers primary solutions, including specialty care management services and administrative services. The company provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

Employees
4,200
Headquarters
Arlington, Virginia
Listed
Jun 5, 2015
Sector
Health Care
Industry
Health Care Technology
Website
evolent.com

EVH key statistics

Market cap
506.51M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.07M
Volume
1.18M
Open price
$4.52
High today
$4.90
Low today
$4.51
52 Week high
$8.30
52 Week low
$2.10

Evolent Health (EVH) at a glance

Evolent Health (EVH) last traded at $4.87, with a market cap of 506.51M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.51 and $4.90. The current price is 8.0% above the day's low and 0.5% below its high.

Volume so far is 1.18M shares, below the average of 2.07M shares a day.

Over the past year Evolent Health has ranged from $2.10 to $8.30, and now sits 45% of the way up that range.

Evolent Health met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.02 per share against an estimate of -$0.0239.

The average analyst price target is $6.63, 36.1% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

79%of 14 analyst ratings say Buy
  • Buy78.6%
  • Hold21.4%
  • Sell0.0%
Price target · 14 analystsAvg $6.63
Low
$3.03
Now
$4.87
High
$15.75

EVH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 94.3% on average.

  1. Q3 FY24: reported $0.04 per share against an estimate of $0.345
  2. Q4 FY24: reported -$0.02 per share against an estimate of $0.0086
  3. Q1 FY25: reported $0.06 per share against an estimate of $0.0964
  4. Q2 FY25: reported -$0.10 per share against an estimate of $0.0791
  5. Q3 FY25: reported $0.05 per share against an estimate of $0.1055
  6. Q4 FY25: reported $0.08 per share against an estimate of $0.0581
  7. Q1 FY26: reported -$0.02 per share against an estimate of -$0.0518
  8. Q2 FY26: reported $0.02 per share against an estimate of -$0.0239

EVH news

  • Press releasePRNewswire

    Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026

  • Press releasePRNewswire

    TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation

  • Press releaseGlobe Newswire

    TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Evolent Announces Second Quarter 2026 Results

  • Press releasePRNewswire

    Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026

  • Press releasePRNewswire

    Quest Analytics Expands Leadership Team with Appointment of Chris Lance as Chief Product Officer

Similar companies

Companies in the same industry as Evolent Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.